科济生物医药（上海）有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA 2022-10-18 20:50
CARsgen 2022 Interim Results: Innovative CAR T-cell Technologies and Robust Pipeline 2022-08-24 20:50
Case Report of Long Term Complete Response in Hepatocellular Carcinoma to CARsgen's GPC3 CAR T Cells (CT011) Published in Frontiers in Immunology 2022-08-18 20:50
CARsgen Appoints Dr. Hua Jiang as Executive Director 2022-08-02 20:50
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022 2022-06-06 20:50
Nature Medicine Publishes Results from an Investigator-Initiated Trial of CARsgen's CT041 Claudin18.2 CAR T Cells in Gastrointestinal Cancers 2022-05-10 20:50
CARsgen Appoints Dr. Raffaele Baffa as Chief Medical Officer 2022-04-07 23:42
CARsgen Announces First Patient Enrollment in the Confirmatory Phase II Clinical Trial of CT041 in China 2022-03-23 20:50
CARsgen 2021 Annual Results: Steady Advancement in Innovative CAR T Products and Technologies 2022-03-23 20:50
Claudin18.2 CAR T Cells (CT041) Receives Approval to Initiate A Confirmatory Phase II Clinical Trial for advanced GC/GEJ in China 2022-03-03 21:50
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation 2022-01-17 21:50
1 2